Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region.
BCLC
cirrhosis
hepatocellular carcinoma
multidisciplinary team
surveillance
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
30
06
2023
received:
10
04
2023
accepted:
20
07
2023
medline:
19
9
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is a growing health concern projected to cross over a million cases worldwide by 2025. HCC presents a significant burden of disease in Middle East and North African (MENA) countries due to a high prevalence of risk factors such as hepatitis C and B infections and rising incidence of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. In August 2022, an advisory meeting consisting of experts from 5 MENA countries was convened in an attempt to provide consensus recommendations on HCC screening, early diagnosis, current treatment modalities and unmet medical needs in the region. Data were collected from a pre-meeting survey questionnaire and responses analysed and presented during the advisory meeting. This review summarizes the evidence discussed at the meeting and provides expert recommendations on the management of HCC. The 2022 update of Barcelona clinic liver cancer (BCLC) staging and treatment strategy and its implementation in the MENA region was extensively discussed. A key consensus of the expert panel was that multidisciplinary care is crucial to effective patient management that results in better clinical outcomes and overall survival of the patient. The panel recommended the use of predictive and early response biomarkers to guide clinicians in arriving at more effective therapeutic decisions. The experts also emphasized the role of robust screening/surveillance systems, population-based registries, effective referral pathways and standardization of guidelines to ensure the successful management of HCC in the region.
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2062-2077Informations de copyright
© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primer. 2021;7(1):1-28. doi:10.1038/s41572-020-00240-3
Cancer (IARC) TIA for R on. Global Cancer Observatory. Accessed November 2, 2022. https://gco.iarc.fr/
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
Colagrande S, Inghilesi AL, Aburas S, et al. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol. 2016;22(34):7645-7659. doi:10.3748/wjg.v22.i34.7645
Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primer. 2016;2:16018. doi:10.1038/nrdp.2016.18
Cancer today. Accessed November 3, 2022. http://gco.iarc.fr/today/home
Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular carcinoma (HCC) in Egypt: a comprehensive overview. J Egypt Natl Cancer Inst. 2020;32(1):5. doi:10.1186/s43046-020-0016-x
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.e1. doi:10.1053/j.gastro.2011.12.061
Liu C, Wu J, Chang Z. Trends and age-period-cohort effects on the prevalence, incidence and mortality of hepatocellular carcinoma from 2008 to 2017 in Tianjin, China. Int J Environ Res Public Health. 2021;18(11):6034. doi:10.3390/ijerph18116034
Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv238-iv255. doi:10.1093/annonc/mdy308
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996-1005.e1. doi:10.1053/j.gastro.2017.06.012
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133. doi:10.1002/hep.29466
Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505-511. doi:10.1038/ng.3252
Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14(27):4300-4308. doi:10.3748/wjg.14.4300
Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683-1691. doi:10.1001/jamaoncol.2017.3055
Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43(6):1303-1310. doi:10.1002/hep.21176
Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):938-945, 945.e1-4. doi:10.1016/j.cgh.2007.02.039
Kamal S. Hepatocellular carcinoma in the Middle East: an overview. In: Carr BI, ed. Liver Cancer in the Middle East. Springer International Publishing; 2021:299-311. doi:10.1007/978-3-030-78737-0_18
Ministry of Health and Population/Egypt, El-Zanaty and Associates/Egypt, ICF International. Egypt health issues survey 2015. 2015. Accessed May 12, 2023. https://dhsprogram.com/publications/publication-fr313-dhs-final-reports.cfm
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-1342. doi:10.1002/hep.26141
Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107-115. doi:10.1111/j.1469-0691.2010.03432.x
Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824-7840. doi:10.3748/wjg.v22.i34.7824
Waked I, Esmat G, Elsharkawy A, et al. Screening and treatment program to eliminate hepatitis C in Egypt. N Engl J Med. 2020;382(12):1166-1174. doi:10.1056/NEJMsr1912628
Omran D, Alboraie M, Zayed RA, et al. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol. 2018;24(38):4330-4340. doi:10.3748/wjg.v24.i38.4330
Micro-elimination of Hepatitis C Virus in the Middle-East_Report of an expert workshop-2.pdf. Accessed November 4, 2022. https://easl-ilf.org/wp-content/uploads/2020/02/Micro-elimination-of-Hepatitis-C-Virus-in-the-Middle-East_Report-of-an-expert-workshop-2.pdf
Mohamoud YA, Riome S, Abu-Raddad LJ. Epidemiology of hepatitis C virus in the Arabian Gulf countries: systematic review and meta-analysis of prevalence. Int J Infect Dis. 2016;46:116-125. doi:10.1016/j.ijid.2016.03.012
Hamoudi W, Ali SAS, Abdallat M, Estes CR, Razavi HA. HCV infection prevalence in a population recruited at health centers in Jordan. J Epidemiol Glob Health. 2013;3(2):67-71. doi:10.1016/j.jegh.2013.02.003
Alswat K, Aljumah AA, Sanai FM, et al. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. Saudi J Gastroenterol. 2018;24(4):211-219. doi:10.4103/sjg.SJG_122_18
Al Romaihi HE, Ganesan N, Farag EA, et al. Demographics and epidemiology of hepatitis B in the State of Qatar: a five-year surveillance-based incidence study. Pathogens. 2019;8(2):68. doi:10.3390/pathogens8020068
Akyıldız M, Ahıskalı E, Zeybel M, Yurdaydın C. Regional epidemiology, burden, and management of hepatitis B virus in the Middle East. Clin Liver Dis. 2020;14(6):212-214. doi:10.1002/cld.887
Sharafi H, Alavian SM. The rising threat of hepatocellular carcinoma in the Middle East and North Africa region: results from global burden of disease study 2017. Clin Liver Dis. 2019;14(6):219-223. doi:10.1002/cld.890
Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598-1606. doi:10.1016/j.jhep.2022.08.021
Almubark RA, Alqahtani S, Isnani AC, et al. Gender differences in the attitudes and management of people with obesity in Saudi Arabia: data from the ACTION-IO study. Risk Manage Healthcare Policy. 2022;15:1179-1188. doi:10.2147/RMHP.S346206
Nawar R, Ibrahim E, Abusnana S, et al. Understanding the gaps in obesity management in the UAE: perceptions, barriers, and attitudes. Dubai Diabetes Endocrinol J. 2021;27(2):37-49. doi:10.1159/000514359
Country Nutrition Profiles. Accessed November 4, 2022. https://globalnutritionreport.org/resources/nutrition-profiles/asia/western-asia/qatar/
Omar A, Abou-Alfa GK, Khairy A, Omar H. Risk factors for developing hepatocellular carcinoma in Egypt. Chin Clin Oncol. 2013;2(4):43. doi:10.3978/j.issn.2304-3865.2013.11.07
Abou El Azm AR, Yousef M, Mansour N, Awad A, El Dardiry S, Abdel AI. New insights on non-B non-C hepatocellular carcinoma in mid Delta Region, Egypt. J Gastrointest Cancer. 2014;45(3):276-283. doi:10.1007/s12029-013-9573-8
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum. 2002;82:1-556.
Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44(4):723-731. doi:10.1016/j.jhep.2005.12.015
Finn RS, Zhu AX, Farah W, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis. Hepatology. 2018;67(1):422-435. doi:10.1002/hep.29486
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-1314. doi:10.1016/S0140-6736(18)30010-2
Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology. 2011;54(6):1998-2004. doi:10.1002/hep.24581
Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19(11):1159-1172. doi:10.1111/j.1365-2036.2004.01963.x
Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. doi:10.1371/journal.pmed.1001624
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358-380. doi:10.1002/hep.29086
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. doi:10.1016/j.jhep.2018.03.019
Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317-370. doi:10.1007/s12072-017-9799-9
Abdo AA, Hassanain M, AlJumah A, et al. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med. 2012;32(2):174-199. doi:10.5144/0256-4947.2012.174
Ahn JC, Lee YT, Agopian VG, et al. Hepatocellular carcinoma surveillance: current practice and future directions. Hepatoma Res. 2022;8:10. doi:10.20517/2394-5079.2021.131
Sherman M. Current status of alpha-fetoprotein testing. Gastroenterol Hepatol. 2011;7(2):113-114.
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-750. doi:10.1002/hep.29913
Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol. 2019;25(13):1550-1559. doi:10.3748/wjg.v25.i13.1550
Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169-177. doi:10.1111/apt.13841
Hong SB, Kim DH, Choi SH, et al. Inadequate ultrasound examination in hepatocellular carcinoma surveillance: a systematic review and meta-analysis. J Clin Med. 2021;10(16):3535. doi:10.3390/jcm10163535
Maruyama H, Sekimoto T, Yokosuka O. Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience. J Gastroenterol. 2016;51(5):421-433. doi:10.1007/s00535-015-1151-3
Daniele B, Bencivenga A, Megna AS, Tinessa V. α-Fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127(5):S108-S112. doi:10.1053/j.gastro.2004.09.023
Lee CW, Tsai HI, Lee WC, et al. Normal alpha-fetoprotein hepatocellular carcinoma: are they really normal? J Clin Med. 2019;8(10):1736. doi:10.3390/jcm8101736
Ahmed Mohammed HF, Roberts LR. Should AFP (or any biomarkers) be used for HCC surveillance? Curr Hepatol Rep. 2017;16(2):137-145. doi:10.1007/s11901-017-0349-7
Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020;371:m3544. doi:10.1136/bmj.m3544. PMID: 33106289.
Teng W, Chang TT, Yang HI, et al. Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. Hepatol Int. 2021;15(6):1421-1430. doi:10.1007/s12072-021-10263-x
Nahon P, Vo Quang E, Ganne-Carrié N. Stratification of hepatocellular carcinoma risk following HCV eradication or HBV control. J Clin Med. 2021;10(2):353. doi:10.3390/jcm10020353
Park H, Kim SU, Park JY, et al. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. Liver Int. 2014;34(2):313-321. doi:10.1111/liv.12274
Abdelaziz A, Mahmoud M, Omran D, et al. Hepatocellular Carcinoma Multidisciplinary Clinic-Cairo University (HMC-CU) score: a new simple score for diagnosis of HCC. Arab J Gastroenterol. 2020;21:21-105. doi:10.1016/j.ajg.2020.04.001
Shiha G, Soliman R, Mikhail NNH, et al. International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients. J Viral Hepat. 2022;29(9):807-816. doi:10.1111/jvh.13717
Ebrahim AE, Shehata MAH, Abou-saif S, Hamisa M, Abd-Elsalam S, Yousef M. Role of Fibroscan for early detection of hepatocellular carcinoma (HCC) in hepatitis C cirrhotic patients. Egypt J Radiol Nucl Med. 2020;51:134. doi:10.1186/s43055-020-00258-3
Ahmed NNA, El Gaafary SM, Elia RZ, Abdulhafiz EM. Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment. Egypt J Radiol Nucl Med. 2020;51(1):102. doi:10.1186/s43055-020-00199-x
Wen N, Cai Y, Li F, et al. The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update. Biosci Trends. 2022;16(1):20-30. doi:10.5582/bst.2022.01061
International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49(2):658-664. doi:10.1002/hep.22709
Renzulli M, Biselli M, Brocchi S, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut. 2018;67(9):1674-1682. doi:10.1136/gutjnl-2017-315384
Kudo M, Kawamura Y, Hasegawa K, et al. Management of Hepatocellular Carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10(3):181-223. doi:10.1159/000514174
Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289(3):816-830. doi:10.1148/radiol.2018181494
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450-1462. doi:10.1056/NEJMra1713263
Scheiner B, Pomej K, Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353-363. doi:10.1016/j.jhep.2021.09.035
Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329-338. doi:10.1055/s-2007-1007122
Draper A. A concise review of the changing landscape of hepatocellular carcinoma. Am J Manag Care. 2020;26(10 Suppl):S211-S219. doi:10.37765/ajmc.2020.88512
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894-1905. doi:10.1056/NEJMoa1915745
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649. doi:10.1002/bjs.1800600817
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681-693. doi:10.1016/j.jhep.2021.11.018
Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: a review of epidemiology and control measures. World J Gastrointest Oncol. 2021;13(12):1919-1938. doi:10.4251/wjgo.v13.i12.1919
Jean K, Tawheed A, Luong Nguye LB, et al. Changes in presentation, treatment, and survival of patients with hepatocellular carcinoma in Damietta, Egypt, 2007-2019: a retrospective monocentric cohort study. J Hepatocell Carcinoma. 2023;10:99-111. doi:10.2147/JHC.S391511
Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293-313. doi:10.1038/s41575-020-00395-0
Shaaban A, Salamah R, Abo Elseud Y, Mohanty A, Albarrak J. Presentation and outcomes of hepatocellular carcinoma in the Arabian Peninsula: a review of a single institution experience in the sorafenib era. J Gastrointest Cancer. 2021;52(1):85-89. doi:10.1007/s12029-019-00341-7
Bryant R, Laurent A, Tayar C, van Nhieu JT, Luciani A, Cherqui D. Liver resection for hepatocellular carcinoma. Surg Oncol Clin N Am. 2008 Jul;17(3):607-633, ix. doi:10.1016/j.soc.2008.02.002
Bhangui P, Vibert E, Majno P, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology. 2011;53(5):1570-1579. doi:10.1002/hep.24231
Al-Judaibi B, Dokus MK, Al-hamoudi W, et al. Saudi Association for the Study of liver diseases and transplantation position statement on the hepatology workforce in Saudi Arabia. Saudi J Gastroenterol. 2022;28(2):101-107. doi:10.4103/sjg.sjg_576_21
Rasul KI, Al-Azawi SH, Chandra P. Hepatocellular Carcinoma in Qatar. 2013;(14):6.
Alqahtani SA, Sanai FM, Alolayan A, et al. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol. 2020;26(Suppl 1):S1-S40. doi:10.4103/sjg.SJG_477_20
Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734-1739. doi:10.1016/S0140-6736(02)08649-X
Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224(1):47-54. doi:10.1148/radiol.2241011262
Kang IK, Kim SW, Hahn SH, Cho SC, Gham CW, Lee DH. A comparison of patients with hepatocellular carcinoma between a short-term (less than 6 months) survival group and a long-term (over 24 months) survival group after treatment with transcatheter arterial chemoembolization. Taehan Kan Hakhoe chi Korean J Hepatol. 2002;8(2):189-200.
Eltawil KM, Berry R, Abdolell M, Molinari M. Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian Centre. HPB. 2012;14(3):162-170. doi:10.1111/j.1477-2574.2011.00420.x
Ahmed ALF, Nasser HM, Abo-Elmaaty MEG, Montasser IF. Role of Transarterial Chemoembolization (TACE) in Down Staging of Hepatocellular Carcinoma (HCC) before Liver Transplantation. Egyptian J Hospital Medicine. 2018;72(12):5578-5583. doi:10.21608/EJHM.2018.11513
Brown DB, Nikolic B, Covey AM, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2012;23(3):287-294. doi:10.1016/j.jvir.2011.11.029
Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348-359. doi:10.1055/s-0032-1329906
Yousuf F, Cross TJ, Palmer D. The ART strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol. 2014;61(1):175. doi:10.1016/j.jhep.2014.02.032
Waked I, Berhane S, Toyoda H, et al. Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer. 2017;116(4):448-454. doi:10.1038/bjc.2016.423
Gui B, Weiner AA, Nosher J, et al. Assessment of the albumin-bilirubin (ALBI) grade as a prognostic indicator for hepatocellular carcinoma patients treated with radioembolization. Am J Clin Oncol. 2018;41(9):861-866. doi:10.1097/COC.0000000000000384
Pinato DJ, Arizumi T, Jang JW, et al. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study. Oncotarget. 2016;7(28):44705-44718. doi:10.18632/oncotarget.9604
Wang Q, Xia D, Bai W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study. J Hepatol. 2019;70(5):893-903. doi:10.1016/j.jhep.2019.01.013
Zhang S, Zhong BY, Zhang L, Wang WS, Ni CF. Transarterial chemoembolization failure/refractoriness: a scientific concept or pseudo-proposition. World J Gastrointest Surg. 2022;14(6):528-537. doi:10.4240/wjgs.v14.i6.528
Gordon A, Lewandowski RJ, Hickey R, et al. Prospective randomized phase 2 study of chemoembolization versus radioembolization in hepatocellular carcinoma: results from the PREMIERE trial. J Vasc Interv Radiol. 2016;27(3):S61-S62. doi:10.1016/j.jvir.2015.12.168
Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35(6):1715-1721. doi:10.1111/liv.12750
Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155-1163.e2. doi:10.1053/j.gastro.2016.08.029
Choi JW, Kim HC. Radioembolization for hepatocellular carcinoma: what clinicians need to know. J Liver Cancer. 2022;22(1):4-13. doi:10.17998/jlc.2022.01.16
Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17-29. doi:10.1016/S2468-1253(20)30290-9
Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res. 2022;10(1):3. doi:10.1186/s40364-021-00350-4
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390. doi:10.1056/NEJMoa0708857
Lencioni R, Kudo M, Ye SL, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract. 2014;68(5):609-617. doi:10.1111/ijcp.12352
Tovoli F, Ielasi L, Casadei-Gardini A, et al. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol. 2019;71(6):1175-1183. doi:10.1016/j.jhep.2019.08.015
Rasul K, Issameldin A, Elazzazi S, Ghasoub R, Gulied A. Can we use Sorafenib for advanced Hepatocellular Carcinoma (HCC) Child Pugh B? Gulf J Oncolog. 2015;1(17):82-84.
Liu W, Quan B, Lu S, et al. First-line systemic treatment strategies for Unresectable hepatocellular carcinoma: a systematic review and network meta-analysis of randomized clinical trials. Front Oncol. 2021;11:771045. doi:10.3389/fonc.2021.771045
Kattah Martinez LX, Marín Carrillo LF, Rojas ML. Sorafenib-induced acute pancreatitis in a patient with differentiated thyroid cancer. Eur Thyroid J. 2018;7(3):145-148. doi:10.1159/000488316
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56-66. doi:10.1016/S0140-6736(16)32453-9
Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54-63. doi:10.1056/NEJMoa1717002
Yamashita T, Kudo M, Ikeda K, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113-122. doi:10.1007/s00535-019-01642-1
Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245-255. doi:10.1002/ijc.25864
Casadei-Gardini A, Rimini M, Tada T, et al. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer. 1990;2023(180):9-20. doi:10.1016/j.ejca.2022.11.017
Trojan J. Cabozantinib for the treatment of advanced hepatocellular carcinoma: current data and future perspectives. Drugs. 2020;80(12):1203-1210. doi:10.1007/s40265-020-01361-5
Blanc JF, Khemissa F, Bronowicki JP, et al. Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with child-Pugh B cirrhosis. Hepatol Int. 2021;15(1):93-104. doi:10.1007/s12072-020-10120-3
Cheng AL, Qin S, Ikeda M, et al. IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann Oncol. 2019;30:ix186-ix187. doi:10.1093/annonc/mdz446.002
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492-2502. doi:10.1016/S0140-6736(17)31046-2
Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77-90. doi:10.1016/S1470-2045(21)00604-5
Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9
Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40(4_suppl):379. doi:10.1200/JCO.2022.40.4_suppl.379
Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995-1008. doi:10.1016/S1470-2045(22)00326-6
Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma. LEAP-002 Fails to Meet Co-primary Endpoints-The ASCO Post. Accessed May 12, 2023. https://ascopost.com/issues/november-10-2022-supplement-conference-highlights-esmo-2022/lenvatinib-plus-pembrolizumab-in-hepatocellular-carcinoma-leap-002-fails-to-meet-co-primary-endpoints/
Griffiths CD, Zhang B, Tywonek K, Meyers BM, Serrano PE. Toxicity profiles of systemic therapies for advanced hepatocellular carcinoma. JAMA Netw Open. 2022;5(7):e2222721. doi:10.1001/jamanetworkopen.2022.22721
Soares KC, Cosgrove DC, Herman JM, Pawlik TM. Multidisciplinary clinic in the management of hepatocellular carcinoma. Ann Surg Oncol. 2014;21(4):1059-1061. doi:10.1245/s10434-013-3419-2
Sinn DH, Choi GS, Park HC, et al. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PloS One. 2019;14(1):e0210730. doi:10.1371/journal.pone.0210730
Tsilimigras DI, Aziz H, Pawlik TM. Critical analysis of the updated Barcelona clinic liver cancer (BCLC) group guidelines. Ann Surg Oncol. 2022;29:7231-7234. doi:10.1245/s10434-022-12242-4
Allaire M, Goumard C, Lim C, Le Cleach A, Wagner M, Scatton O. New frontiers in liver resection for hepatocellular carcinoma. JHEP Rep. 2020;2(4):100134. doi:10.1016/j.jhepr.2020.100134